Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
J. Clin. Invest. Raffaele Ciampi, et al. 115:94 doi:10.1172/JCI23237 [Go to this article.]

Figure 5
Analysis of post-Chernobyl tumors that developed 5–6 years after exposure. (A) Southern blot of RT-PCR products amplified with primers Ex8A and Ex10B and hybridized with probe PR showing 2 positive cases (C32 and C27). Other tumor samples are negative (C13, C23, C24, C18, and C31). NC, negative control; PC, positive control (index case). (B) Immunohistochemical analysis of tumor C32 with AKAP9 antibody showing a shift in subcellular localization of the protein from a single dot/centrosomal pattern observed in the entrapped non-neoplastic follicles (arrows) to diffuse cytoplasmic staining in tumor cells. Magnification, ×200.